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The Journal of Immunology
Inhibition of CD73 Improves B Cell-Mediated Anti-Tumor
Immunity in a Mouse Model of Melanoma
Giovanni Forte,* Rosalinda Sorrentino,* Antonella Montinaro,* Antonio Luciano,†
Ian M. Adcock,‡ Piera Maiolino,† Claudio Arra,† Carla Cicala,x Aldo Pinto,* and
Silvana Morello*
CD73 is a cell surface enzyme that suppresses T cell-mediated immune responses by producing extracellular adenosine. Growing
evidence suggests that targeting CD73 in cancer may be useful for an effective therapeutic outcome. In this study, we demonstrate
that administration of a specific CD73 inhibitor, adenosine 59-(a,b-methylene)diphosphate (APCP), to melanoma-bearing mice
induced a significant tumor regression by promoting the release of Th1- and Th17-associated cytokines in the tumor microenvi-
ronment. CD8+ T cells were increased in melanoma tissue of APCP-treated mice. Accordingly, in nude mice APCP failed to reduce
tumor growth. Importantly, we observed that after APCP administration, the presence of B cells in the melanoma tissue was
greater than that observed in control mice. This was associated with production of IgG2b within the melanoma. Depletion of
CD20+ B cells partially blocked the anti-tumor effect of APCP and significantly reduced the production of IgG2b induced by
APCP, implying a critical role for B cells in the anti-tumor activity of APCP. Our results also suggest that APCP could influence
B cell activity to produce IgG through IL-17A, which significantly increased in the tumor tissue of APCP-treated mice. In support
of this, we found that in melanoma-bearing mice receiving anti–IL-17A mAb, the anti-tumor effect of APCP was ablated. This
correlated with a reduced capacity of APCP-treated mice to mount an effective immune response against melanoma, as neutral-
ization of this cytokine significantly affected both the CD8+ T cell- and B cell-mediated responses. In conclusion, we demonstrate
that both T cells and B cells play a pivotal role in the APCP-induced anti-tumor immune response. The Journal of Immunology,
2012, 189: 2226–2233.
C
ancer cells are able to escape immune surveillance
through multiple mechanisms, including the production
of immunosuppressive factors in the tumor microenviron-
ment that can impair immune cell function (1). Adenosine plays an
important role in the mechanism of tumor escape (2, 3). Adeno-
sine is an ATP-derived nucleoside, highly released during hypoxic
conditions typical of tumor microenvironment (4). In this context,
cancer cells rapidly degrade ATP into adenosine, which in turn
accumulates in the tumor mass (5). Adenosine inhibits T cell
proliferation (6) and critically impairs the cytokine production
and the cytotoxicity of activated T cells (7, 8), protecting the tu-
mor from immune-mediated destruction (2). Adenosine thus rep-
resents an important immunosuppressive molecule in the tumor
microenvironment that limits the activation of the immune system
to eradicate cancer cells (3, 9).
Extracellular adenosine is produced from the cells by two ecto-
nucleotidases:CD39,whichhydrolyzesATPandADP intoAMP;and
CD73, which catalyzes AMP conversion into adenosine. CD73 is the
rate-limiting enzyme in this process (10) and is expressed on different
cell types, including endothelial and epithelial cells (11), subsets of
leukocytes (12), and Foxp3+ regulatory T cells (Tregs) (13). Notably,
CD73 is upregulated in several types of cancers (14), and growing
evidence suggests that CD73 plays a crucial role in the control of
tumor progression. Indeed, it has been demonstrated that inhibition
of CD73 activity (15) or CD73 knockdown on tumor cells (16)
inhibits tumor growth by enhancing the anti-tumor T cell response.
More recently, by using CD73-deficient mice, it has been shown that
CD73 on hematopoietic cells (including Foxp3+ Tregs) impairs the
anti-tumor T cell-mediated immune response (17, 18). These effects
are attributed to the regulation of extracellular adenosine generated
by CD73 within the tumor microenvironment (17, 18).
In the current study, we determined the therapeutic anti-tumor
efficacy of a specific inhibitor of CD73, adenosine 59-(a,b-methylene)
diphosphate (APCP). We provide new insights into the mecha-
nism(s) underlying the anti-tumor activity of APCP in a mouse
model of melanoma. Our results indicate that administration of
APCP inhibited tumor growth by promoting a Th1- and Th17-like
immune response in the tumor environment. These effects are cor-
related with a higher presence of tumor-infiltrating CD8+ T cells.
Moreover, we show that B cells are also required for the anti-
tumor effects induced by APCP, as Ig-producing cells. Indeed,
depletion of CD20+ B cells significantly reduced the anti-tumor
effects of APCP and the production of APCP-induced IgG2b.
Furthermore, we found that the anti-tumor activity of APCP is
dependent on IL-17A, which in turn affects the APCP-induced
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cytotoxic immune response and the levels of IgG2b within the
melanoma tissue.
Materials and Methods
Mice
C57BL/6j and Athymic Nude-Foxn1nu mice were purchased from Harlan
Laboratories (Udine, Italy). Mice were maintained in the National Cancer
Institute “G. Pascale” Animal Facility (Naples, Italy), according to insti-
tutional animal care guidelines, Italian D.L. no.116 of January 27, 1992,
and European Communities Council Directive of November 24, 1986 (86/
609/ECC).
Cell culture and CD19+ B cell isolation
B16-F10 mouse melanoma cells were from American Type Culture Col-
lection (LGC Standards S.r.l., Milan, Italy), and K1735 mouse melanoma
cells were kindly provided by Dr. Silvio Hemmi (University of Zurich,
Zurich, Switzerland). Cells were cultured in complete DMEM containing
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 U/ml strep-
tomycin (Sigma-Aldrich, Milan, Italy).
CD19+ B cells were purified from the spleens of naive C57BL/6j mice
by magnetic separation using a CD19+ cell isolation kit according to the
manufacturer’s instructions (EasySep Stem Cell; Voden, Milan, Italy). The
purity of CD19+ B cells was checked by flow cytometry by using anti-
CD19 and anti-B220 Abs (eBioscience, San Diego, CA) and was routinely
around 90%. CD19+ B cells were cultured in RPMI 1640 enriched with
10% FBS and treated with APCP (5 mM; Sigma-Aldrich, Milan, Italy) for
24 h. Supernatants were analyzed for cytokine production by ELISA, and
cells were stained with the markers MHC class I, MHC class II, and CD20
and analyzed by FACS.
Animal studies
Mice (female at 6–8 wk old) were injected s.c. on the right flank with 3 3
105 B16-F10 cells or with 5 3 105 K1735 cells. APCP (400 mg/mouse)
was delivered to the mice by the peritumoral (p.t.) route on day 10 and day
12 after tumor injection. This time point was selected in preliminary
studies as it achieved optimal anti-tumor effects. Tumor volume was
monitored with a digital caliper and calculated using the formula V = 4/3
p 3 (D/2) 3 (d/2)2, where V = volume (mm3), D = long diameter (mm),
and d = short diameter (mm). Mice were sacrificed on day 13 after tumor
cell implantation, and melanoma tissues and proximal lymph nodes were
isolated for further analyses. In some experiments, an anti-CD73 mAb
(TY/23, 10 mg/mouse, p.t.) was administered to melanoma-bearing mice as
described for APCP.
In some experiments, an anti-CD20 mAb (rat IgG, 250 mg/mouse in 100
ml PBS; eBioscience) (19, 20) was injected i.p. on the same day that mice
received APCP (day 10), and mice were sacrificed on day 13. The anti-
CD20 mAb depleted splenic CD20+ B cells by 90% compared with IgG, as
previously demonstrated in our laboratory (20).
In other experiments, a neutralizing mAb against IL-17A (clone
eBioMM17F3, mouse IgG, 20 mg/mouse; eBioscience) was injected i.p.
every day starting from day 10 until day 13. The anti–IL-17A mAb re-
duced IL-17A release in the melanoma tissue by ∼95% compared with IgG
(data not shown).
Cell analysis
Tumors, lymph nodes, and spleens were digested with 1 U/ml collagenase A
(Sigma-Aldrich, Milan, Italy). Cell suspensions were passed through 70-mm
cell strainers, and RBCs were lysed. The cells were used for flow cyto-
metric analyses (Becton Dickinson FACSCalibur, Milan, Italy). The fol-
lowing Abs were used: CD8–PE, CD3–PeCy5.5, CD4–FITC, CD25–PE,
Foxp3–PeCy5.5, NK1.1–PE, CD11c–FITC, CD19–PeCy5.5, and B220–PE
(eBioscience). Further characterization was performed by using the fol-
lowing Abs: CD3–PECy5.5, CD8–allophycocyanin, CD4–allophycocya-
nin, IFN-g–PE, and IL-17–PE (eBioscience).
ELISA
IL-17A, TNF-a, IFN-g, IL-10, TGF-b, and IgG2b were detected in mel-
anoma tissue homogenates by using mouse-specific ELISA kits (eBio-
science, San Diego, CA; R&D Systems, Abingdon, U.K.; Bethyl Laboratories,
Montgomery, TX).
Immunohistochemistry
For histological analysis, melanoma tissues were fixed in OCT medium
(Pella, Milan, Italy) and cut in 7-mm cryosections. Frozen sections were
stained with Ki67 (Abcam, Cambridge, U.K.) or Bcl-2 (Santa Cruz Bio-
technology, DBA, Milan, Italy) and detected with FITC anti-rabbit or FITC
anti-mouse secondary Abs, respectively. In all staining experiments,
isotype-matched IgG and omission of the primary Ab was used as negative
control. Slides were analyzed by a fluorescence microscope (Carl Zeiss,
Milan, Italy) by means of the Axioplan Imaging Program (Carl Zeiss).
Immunoblot analysis
Tumor tissues were homogenized in RIPA buffer (RIA Precipitation
Buffer). Anti–Bcl-2 (Santa Cruz Biotechnology, DBA, Milan, Italy) or
anti-tubulin Abs (Sigma-Aldrich, Rome, Italy) were used. Immunoreactive
proteins were quantified by densitometry analysis (GelDoc Instrument).
Statistical analysis
Results are expressed as mean 6 SEM. All statistical differences were
evaluated by either Student t test or one-way ANOVA, followed by Bon-
ferroni’s posttest as appropriate, and p values ,0.05 were considered
statistically significant.
Results
APCP-induced tumor regression is associated with increased
release of Th17- and Th1-like cytokines
To investigate the effect of CD73 blockade on tumor growth, we
used APCP, which has successfully been used in various murine
models, including those for cancer (16, 18, 21).
C57BL/6j mice were s.c. injected with 3 3 105 B16-F10 cells,
and 10 d later mice were treated with APCP (400 mg/mouse, p.t.).
The administration of APCP significantly reduced tumor growth in
melanoma-bearing mice compared with PBS-treated mice (APCP
254.4 6 65.8 mm3 versus PBS 816.2 6 259.2 mm3; p , 0.01)
(Fig. 1A). To verify the effect of APCP on melanoma growth, we
also evaluated the expression of Ki67, a proliferation marker (22).
We observed a significant reduction in cells staining for Ki67
when mice were treated with APCP (Fig. 1B, 1C). In addition,
expression of Bcl-2, an antiapoptotic protein (23), was reduced in
tissue sections harvested from mice treated with APCP compared
with that in tissue sections harvested from mice treated with PBS
(Fig. 1D, 1E). Thus, mice receiving APCP exhibited reduced tu-
mor growth compared with control, consistent with previous studies
(16, 18, 21). This effect was associated with a reduction in the
number of proliferating cells within the tumor and increased sus-
ceptibility of cells to apoptosis.
CD73-derived adenosine can modulate the inflammatory re-
sponse (24); therefore, we analyzed the levels of cytokines (IFN-g,
TNF-a, IL-17A, IL-10, TGF-b) in the homogenates of melanoma
tissue harvested from the APCP-treated mice described earlier.
Notably, we found that the levels of IL-17A, a proinflammatory
cytokine, were significantly increased in the tumor tissue after
APCP treatment (Fig. 1F). Mice receiving APCP also showed
increased release of the Th1-associated cytokines TNF-a and
IFN-g (Fig. 1G and 1H, respectively), whereas the levels of both
IL-10 and TGF-b were not elevated in the tissue of mice treated
with APCP (Fig. 1I and 1J, respectively). APCP is a well-known
CD73 inhibitor, and the possibility of off-target effects in vivo
cannot be ruled out. However, similar results were obtained in
mice administered with the anti-CD73 mAb TY/23 (Fig. 2A–C).
The anti-tumor activity of APCP was also evaluated in the
K1735 tumor model. C57BL/6j mice were s.c. injected with K1735
melanoma cells, and 8 d later APCP was administered as previ-
ously described. APCP treatment significantly reduced tumor
growth (Fig. 2D). This effect was associated with increased levels
of IFN-g (Fig. 2E) and IL-17A (Fig. 2F) in the tumor tissue.
These results indicate that the anti-tumor effect of APCP in
melanoma-bearing C57BL/6j mice was accompanied by high
production of Th1- and Th17-like cytokines within tumor tissue.
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APCP treatment increased tumor-infiltrating B cells
Previous studies showed that tumor growth is inhibited in CD73-
deficient mice because of the improved T cell-mediated response
(17, 18). Our results described above show that inhibition of tumor
growth by APCP administration in melanoma-bearing mice corre-
lated with cytokines associated with Th17- and Th1-like immune
responses in the melanoma. Consistent with previous reports (18),
the percentage of tumor-infiltrating CD3+CD8+ T cells was in-
creased after APCP treatment (Fig. 3A, 3B), whereas the percentage
of CD4+ T cells, NK1.1+ cells, NKT cells, and Foxp3+ Tregs were
not altered (Supplemental Fig. 1A–D). Surprisingly, we found that
APCP increased the number of infiltrating B cells (CD19+B220+
cells) within the melanoma tissue (Fig. 3C, 3D). This was associ-
ated with increased levels of the IgG2b in the tumor tissue (Fig. 3E),
whereas the levels of IgM (PBS 0.155 6 0.02 ng/mg protein versus
APCP 0.1136 0.01 ng/mg protein, n = 11) and IgG2a (PBS 1.386
0.21 ng/mg protein versus APCP 1.416 0.35 ng/mg protein, n = 7)
were unaltered, and IgG1 and IgG3 were not detectable.
These results indicate that the tumor regression observed in mice
receiving the CD73 inhibitor APCP is associated with an increased
percentage of tumor-infiltrating CD8+ T cells. Moreover, the data
suggest that APCP administration increased the numbers of
B cells and the production of IgG2b within the melanoma tissue.
B cells contribute to the anti-tumor effects induced by APCP in
melanoma-bearing mice
To determine whether administration of APCP could directly reg-
ulate B cell function, we performed in vitro experiments on isolated
B cells. CD19+ B cells were isolated from spleen of naive C57BL/
6j mice and cultured for 24 h with APCP (5 mM) or PBS. APCP
treatment did not affect either B cell production of IL-10, IL-17A,
and TNF-a (Supplemental Fig. 2A, 2B, and 2C, respectively) or
MHC class I, MHC class II, and CD20 expression on B cells
in vitro (Supplemental Fig. 2D, 2E, and 2F, respectively). Thus,
although APCP was unable directly to influence B cell function
in vitro, data obtained in mice indicate that inhibition of CD73 in
the tumor environment may affect the humoral immune response.
To assess the role of B cells in the anti-tumor effect of APCP
in vivo, we treated mice with APCP or PBS (on day 10 and 12 after
B16-F10 injection) after B cell depletion using an anti-CD20 mAb
injected i.p. on day 10 (Fig. 4A). The anti-CD20 mAb treatment
alone did not significantly affect tumor growth in melanoma-
bearing mice (Fig. 4B). The anti-tumor effect of APCP was par-
tially reduced in CD20+ B cell-depleted mice compared with IgG
plus APCP-treated mice (anti-CD20 mAb plus APCP 617.75 6
107.1 mm3 versus IgG plus APCP 299.54.24 6 71.37 mm3; p ,
0.01) (Fig. 4B). To examine further the effect of APCP in CD20+
FIGURE 1. APCP administration significantly reduced tumor growth in melanoma-bearing C57BL/6j mice. (A) Tumor volume (mm3) was significantly
reduced in mice receiving APCP (400 mg/mouse, p.t.) compared with that in control mice (PBS) (n = 13). (B and C) Ki67 expression was determined by
immunofluorescence staining in melanoma cryosections harvested from PBS- and APCP-treated mice (original magnification 320) (B) and quantified as
number of Ki67+ cells per mm2 of melanoma section by using ImageJ Software (National Institutes of Health) (n = 6) (C). (D and E) The expression of the
antiapoptotic protein Bcl-2 in melanoma cryosections by immunofluorescence staining and in tissue lysates by Western blotting, respectively, of mice
treated with PBS or APCP. Images are representative of n = 5 (original magnification 320). (F–J) Levels of IL-17A, TNF-a, IFN-g, IL-10, and TGF-b,
respectively, measured in the tissue homogenate of mice treated with PBS or APCP (n = 13). Results are from three independent experiments and are
expressed as mean 6 SEM. *p , 0.05, **p , 0.01, ***p , 0.001 (one-way ANOVA or Student t test, as appropriate).
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B cell-depleted mice, we analyzed the tumor-infiltrating cells.
Neither the percentage of APCP-induced IFN-g+CD8+ T cells
(Fig. 4C) nor IFN-g levels (Fig. 4D) were significantly affected
in B cell-depleted mice after APCP administration. The percent-
age of IFN-g+CD4+ T cells, which was similar in all groups, is
also shown (Fig. 4C). CD20+ B cell depletion, however, prevented
APCP-induced levels of IgG2b within the melanoma compared with
IgG-treated mice (Fig. 4E). This suggests that IgG2b-producing
B cells significantly contributed to the anti-tumor effects induced
by APCP in melanoma-bearing mice.
FIGURE 2. Administration of anti-CD73 mAb, TY/23 (10 mg/mouse, p.t.), reduced tumor growth in B16-F10 melanoma-bearing mice (A) and increased
the levels of IFN-g (B) and IL-17 (C) in the tumor tissue. APCP treatment reduced tumor volume in mice bearing K1735 tumors (D) and increased the levels
of IFN-g (E) and IL-17 (F) in the tumor tissue. Results are expressed as mean6 SEM (n = 5). *p, 0.05, **p, 0.01 (one-way ANOVA or Student t test, as
appropriate).
FIGURE 3. APCP administration promotes both the recruitment of CD8+ T cells and B cells within tumor lesion. Percentage of CD8+ T cells (A) and B
cells (C) in tumor tissue by gating on CD3+CD8+ T cells and CD19+B220+, respectively. Representative dot plots are shown in (B) and (D). (E) IgG2b levels
detected by means of ELISA in tumor tissue homogenates. Results are from three independent experiments and are expressed as mean 6 SEM, n = 10.
*p , 0.05 (Student t test).
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In B cell-depleted animals, we observed that although anti-CD20
mAb treatment can affect IL-17A production (25, 26), APCP
treatment increased the levels of IL-17 in the tumor tissue (Fig.
4F). Moreover, we found that APCP-treated mice had increased
tumor-infiltrating IL-17+CD4+ T cells (Fig. 4G). The number of
tumor-infiltrating IL-17+CD8+ T cells was similar in all treated
groups (Supplemental Fig. 3).
APCP-induced anti-tumor effect is dependent on IL-17A
To understand the role of IL-17A in APCP-induced tumor growth
regression, B16-F10–implanted C57BL/6j mice were injected
with a neutralizing Ab for IL-17A (20 mg/mouse, i.p.) or IgG
control (mouse IgG) every day starting from day 10 after tumor
cell implantation (Fig. 5A). Mice were treated with APCP or
PBS on day 10 and 12 and sacrificed on day 13 as described
earlier (Fig. 5A). Administration of the IL-17A mAb did not alter
tumor growth in melanoma-bearing mice (Fig. 5B). In contrast,
IL-17A neutralization significantly blocked the anti-tumor effect
of APCP (anti–IL-17A mAb plus APCP 704.18 6 98.4 mm3
versus IgG plus APCP 379.73 6 78.9 mm3; p , 0.05) (Fig. 5B).
In addition, both the percentage of tumor-infiltrating CD8+ T cells
(Fig. 5C) and the production of IFN-g within tumor tissue (Fig.
5D, Supplemental Fig. 4) were significantly reduced after APCP
treatment in IL-17A–depleted mice. Blockade of IL-17A also
significantly reduced both the percentage of B cells (Fig. 5E) and
the levels of APCP-induced IgG2b within the tumor mass (Fig.
5F).
Together these results suggest that blockade of CD73 is asso-
ciated with high IL-17A production in the tumor environment.
Moreover, this cytokine is critical for the observed anti-tumor effect
of APCP. Indeed, the results suggest that APCP-induced IL-17A
could positively influence both CD8+ T cell- and B cell-mediated
responses within the tumor.
APCP did not affect tumor growth in nude mice
We further investigated the effect of APCP on tumor growth in
athymic nude mice, which lack T cells. Nude mice were injected
with B16-F10 cells, and 10 d later mice were twice administered
with APCP as described earlier for C57BL/6j mice. Tumor growth
in nude mice was not affected by APCP treatment (APCP 990.46
414.7 mm3 versus PBS 1066.8 6 520.4 mm3) (Fig. 6A). These
results confirm that T cells are required for the APCP-induced
regression of melanoma. Additionally, APCP treatment did not
modulate B cell activation or IgG2b levels in nude mice (Fig. 6B).
These data further support the concept that APCP could indirectly
influence B cell activity to produce IgG by inducing inflammatory
T cell-associated cytokines, such as IL-17A, which we could not
detect in these mice (data not shown).
FIGURE 4. Depletion of CD20+ B cells reduced the anti-tumor effect of APCP in melanoma-bearing mice. (A) Experimental protocol: anti-CD20 mAb
(250 mg/mouse, i.p.) was administered on day 10 after B16-F10 tumor cell implantation, when mice received APCP (400 mg/mouse). (B) Tumor volume
(mm3) in mice receiving anti-CD20 mAb or isotype control IgG after APCP or PBS administration. Representative dot plots of IFN-g+ cells gated on CD3+
CD8+ T cells or CD3+CD4+ T cells are shown (C). (D–F) Levels of IFN-g, IgG2b, and IL-17, respectively, in the melanoma tissue of mice receiving anti-
CD20 mAb (black bar) or IgG (white bar) after APCP or PBS administration. (G) Representative dot plots for IL-17+ gated on CD3+CD4+ T cells in the
tumor tissue are shown. Results are from three independent experiments and are expressed as mean 6 SEM, n = 10. *p , 0.05, **p , 0.01, ***p , 0.001
(one-way ANOVA).
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Discussion
In this study, we provided new insights into the mechanism un-
derlying the anti-tumor activity of APCP, a CD73 inhibitor, in
a mouse model of melanoma. Administration of APCP facilitated
a local Th1- and Th17-associated cytokine release, which in turn
affects tumor cell growth. Similar results were observed using
an anti-CD73 mAb. Importantly, we observed that the anti-tumor
activity of APCP in mice is mediated, at least in part, by B cells
producing IgG2b within the tumor lesion.
Several studies have shown that CD73 via adenosine generation
can promote tumor growth in mice. Adenosine derived from CD39
in concert with CD73, expressed both on tumor cells and on host
cells (including Tregs), accumulates within tumor tissue dampening
anti-tumor T cell immunity (13, 15, 16). Moreover, tumor-associated
Tregs, which highly express CD39 and CD73, inhibit Th17 cell
development through the adenosinergic pathway (27). The tumor
resistance of CD73-deficient mice is associated with an increased
influx of CD8+ T cells (18) and low numbers of Tregs within the
tumor (21). Of note, anti-CD73 mAb therapy or blockade of CD73
significantly inhibits tumor growth (15, 18) and enhances the effi-
cacy of adoptive T cell therapy (18). In our study, we found that the
anti-tumor effect of APCP was associated with a greater presence of
melanoma-infiltrating CD8+ T cells. These data further indicate
that the anti-tumor activity of APCP in immune-competent mice,
bearing B16-F10 melanoma, is T cell-dependent. Accordingly, in
nude mice APCP failed to reduce tumor growth. This study is the
first, to our knowledge, to demonstrate that B cells are also involved
in the anti-tumor effect of APCP in mice.
Several studies have shown that B cells play an important role in
the anti-tumor immunity. For example, B cell-deficient mice (28,
29) or mice depleted of B cells (30–32) are protected from tumor
proliferation. These results may be due to the activation status of
B cells (33) and/or the immune-regulatory function of B cells
(B10 cells), which produce IL-10 (34). In contrast, recent stud-
ies demonstrate that B cells facilitate T-mediated responses, which
in turn impair tumor development (19, 20). These observations
indicate that B cells can significantly contribute to control tumor
growth. In addition, activated B cells can mediate significant tu-
FIGURE 5. The anti-tumor effect of APCP in melanoma-bearing C57BL/6j mice is IL-17A mediated. (A) Experimental protocol: anti–IL-17A mAb (20
mg/mouse, i.p.) was administered every day starting from day 10 after B16-F10 tumor cell implantation, when mice received APCP (400 mg/mouse). (B)
Tumor volume (mm3) in mice receiving anti-IL-17A mAb or isotype IgG control and treated with PBS or APCP. Percentage of CD8+ T cells recruited in the
tumor tissue (C) and levels of IFN-g in the tumor mass (D) of mice receiving isotype IgG control (white bar) or anti–IL-17A mAb (black bar) and treated
with PBS or APCP. In (E) and (F) are reported the percentage of tumor-infiltrating B cells and the tissue levels of IgG2b, respectively, in mice receiving
isotype IgG control (white bar) or anti–IL-17A mAb (black bar). Results are from three independent experiments and are expressed as mean6 SEM, n = 9.
*p , 0.05, ***p , 0.001 (one-way ANOVA).
FIGURE 6. APCP administration did not affect tumor growth in nude
mice. Athymic nude mice bearing melanoma B16 cells were treated with
APCP 10 d after tumor cell implantation. (A) Tumor growth after APCP or
PBS treatment. (B) IgG2b levels in the tumor tissue harvested from nude
mice treated with APCP or PBS. Results are from two independent
experiments and are expressed as mean 6 SEM, n = 6.
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mor regression in an IgG2b-dependent manner (20, 35). These
latter studies highlight the effector function of B cells as a source
of IgG2b that are highly cytotoxic toward tumor cells (35).
Many studies report that the majority of B cells do not express
CD73 (12), although some authors have demonstrated that CD73
is expressed on a subset of memory B cells (36), suggesting that
CD73-derived adenosine could regulate B cell function (36, 37).
However, as yet the role of CD73 in regulating B cell function has
not been clearly defined. In the current study, we observed in-
creased numbers of B cells in the melanoma tissue of APCP-
treated mice. This result is associated with enhanced production
of IgG2b in the tumor mass. Depletion of CD20+ B cells markedly
reduced the anti-tumor effect of APCP and the level of IgG2b
enhanced by APCP, further supporting the notion that B cells
mediated the activity of APCP in reducing tumor growth as Ig-
producing cells. Further work is needed to assess the importance
of the IgG2b-mediated response in the therapeutic activity of
APCP. APCP could indirectly affect the in vivo B cell activity to
produce IgG by inducing the release of cytokines, such as IL-17,
into the tumor microenvironment. IL-17A is a proinflammatory
cytokine implicated in the pathogenesis of autoimmunity (38);
however, the role of IL-17A in tumor immunity is controversial, as
both pro- and anti-tumor effects have been described. In immune-
deficient mice, IL-17A overexpressed in tumor cells enhanced
tumor growth by promoting angiogenesis (39). Similar results
have been obtained in IL17a2/2mice (40). In contrast, other studies
demonstrated that IL-17A inhibits tumor growth in immune-
competent mice through enhanced anti-tumor immunity (41,
42). Recent studies also show that Th17 cells protect mice from
tumor proliferation by facilitating the activation of CD8+ T cells
and NK cells (43, 44). Similarly, IL-17 produced by cytotoxic
CD8+ T cells (Tc17) inhibit B16-F10 melanoma growth (45).
The current study shows that APCP administration leads to
enhanced production of T cell-derived IL-17Awithin tumor tissue,
suggesting that inhibition of CD73 could condition CD4+ T cell
polarization toward Th17-producing cells. This hypothesis is
supported by previous data on adenosine-induced suppression of
Th17 development. It has been reported that hydrolysis of ATP
to adenosine or adenosine analogues reduces IL-17 production
by CD4+ T cells (46). Notably, Th17 cells in the tumor microen-
vironment are negatively associated with the presence of Tregs,
which suppress Th17 cells through adenosine induction (27). In-
hibition of ectonucleotidases, highly expressed on Tregs, recov-
ered T cell IL-17 production (27).
We found that IL-17A blockade prevents the ability of APCP
to inhibit tumor growth. This effect was correlated with a reduced
presence of CD8+ T cell and reduced IFN-g production in the
melanoma tissue of APCP-treated mice. Although previous data
indicate that IL-17A drives T cell recruitment (43), the effects on
proliferation and/or survival may also be important. Notably, our
results also suggest that APCP-induced IL-17A facilitates the
presence of B cells within the tumor tissue and the production of
IgG2b. Recent data indicate that IL-17A can positively regulate
the humoral immune response. IL-17A promotes germinal center
formation and class switch recombination to IgG subclasses (47,
48). Moreover, IL-17A sustains the proliferation of B cells and
their differentiation into Ig-secreting cells in systemic lupus
erythematosus (49). This supports our concept that APCP-induced
IL-17Awithin the tumor tissue is essential for the regulation of the
local B cell response. It is currently unclear what is the relative
role of the other cytokines such as TNF-a and IFN-g, which were
elevated in melanoma tissue, in comparison with that of IL-17A
in regulating the T cell and B cell recruitment, proliferation, and
survival in response to APCP treatment in this model. Further
work in this area is needed to elucidate these aspects of the anti-
tumor effect of APCP.
In conclusion, our data demonstrate that in addition to T cells,
B cells also contribute to the anti-tumor activity of APCP in mice
via an IL-17A–mediated process. Thus, pharmacological inhibi-
tion of CD73 in the tumor tissue exerts a beneficial therapeutic
effect by mounting a protective B cell- and T cell-mediated anti-
tumor response.
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